Tvardi Therapeutics to Present at the 8th Annual IPF Summit

HOUSTON--(BUSINESS WIRE)--Tvardi Therapeutics, Inc. (“Tvardi”), a privately held, clinical-stage biopharmaceutical company developing novel STAT3 inhibitors for fibrotic diseases, chronic inflammatory diseases and diverse cancers, today announced that Imran Alibhai, PhD, Chief Executive Officer of Tvardi Therapeutics, was selected to make a presentation and co-lead a panel discussion at the 8^th Annual IPF Summit being held in Boston, MA on August 22, 2024.

Presentation Title: Unveiling TTI-101 as a Novel Approach in Pulmonary Fibrosis & Interstitial Lung Disease Treatment
Session: Examining the Future Directions of the Pulmonary Fibrosis Landscape to Bring Better Drugs to Patients Faster
Date & Time: Thursday, August 22, 2024, at 3:45 PM ET

Panel Discussion Title: Unravelling the Rationale Behind Combination Therapy & Critical Design & Development Considerations for Emerging Therapeutic Candidates
Session: Looking Beyond Monotherapy & The Current Standard of Care to Combining Existing & Emerging Therapeutics for a Combination Approach
Date & Time: Thursday, August 22, 2024, at 10:00 AM ET

The IPF Summit is the largest drug development initiative for the pulmonary fibrosis community, bringing together key biopharmaceutical companies, clinicians, and academic researchers from around the globe. For more information about the IPF Summit, please visit ipf-summit.com.

About Tvardi Therapeutics

Tvardi is a privately held, clinical-stage biopharmaceutical company developing small molecule inhibitors of STAT3, a key regulatory protein that plays a central role in the pathogenesis of many fibrotic and inflammatory diseases. STAT3 is also positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. The company is conducting Phase 2 clinical trials in STAT3-driven diseases: idiopathic pulmonary fibrosis (NCT05671835) and hepatocellular carcinoma (NCT05440708). To learn more, please visit tvardi.com or follow us on LinkedIn and X (Twitter).